Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-005 injection in paroxysmal nocturnal hemoglobinuria – phase II extension
CTR20254745Phase 2Active
- Sponsor
- LongBio Pharma
- Start
- Dec 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LP-005 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by LongBio Pharma. Started Dec 2025; status: active.
02
Drugs
LP-005
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20254745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254745.